PROPANC BIOPHARMA, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | $28.1K | $30.5K |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $223.7K | $248.1K | $247.9K | $256.1K | $231.0K | $180.0K | $260.3K | $1.8M |
| SG&A Expense | $57.0M | $1.3M | $1.5M | $1.7M | $1.6M | $3.3M | $2.3M | $2.1M |
| Operating Income | $-57.3M | $-1.5M | $-1.8M | $-2.0M | $-1.8M | $-3.5M | $-2.6M | $-4.0M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | $532.8K | $568.8K | $449.5K | $1.7M | $1.3M | $2.8M |
| Pretax Income | $-58.9M | $-1.9M | $-2.8M | $-2.7M | $-2.1M | $-4.9M | $-5.8M | $-7.0M |
| Income Tax Expense | — | $-129.1K | $-129.8K | $-55.0K | $-113.4K | $-134.7K | $-115.4K | $-179.3K |
| Net Income | $-58.9M | $-1.8M | $-2.7M | $-2.7M | $-2.0M | $-4.7M | $-5.8M | $-7.0M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-14.85 | $-1,420.53 | $-0.04 | $-0.04 | $0.00 | $-0.16 | $-0.01 | $-0.15 |
| EPS (Diluted) | $-14.85 | $-1,420.53 | $-0.04 | $-0.04 | $0.00 | $-0.16 | $-0.01 | $-0.15 |
| Shares Outstanding (Basic) | 4.0M | 85.0M | 85.2M | 83.57B | 3.71B | 843.62B | 1.43B | 198.50B |
| Shares Outstanding (Diluted) | 4.0M | 85.0M | 85.2M | 83.6M | 3.71B | 843.62B | 1.43B | 198.50B |
| Dividends Per Share | — | — | — | — | — | — | — | — |